MML Investors Services
TGTX icon

MML Investors Services’s TG Therapeutics TGTX Stock Holding History

MML Investors Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Buy
11,931
+5,527
+86% +$226K ﹤0.01% 2277
2026
Q1 		$213K Sell
6,404
-4,742
-43% -$141K ﹤0.01% 2789
2025
Q4 		$332K Buy
+11,146
New +$364K ﹤0.01% 2553

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

MML Investors Services's TGTX Position: Q2 2026 in Review

MML Investors Services increased its TG Therapeutics (TGTX) stake by 86% in Q2 2026, buying an estimated $226K and bringing the position to 11,931 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

MML Investors Services first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • MML Investors Services held 11,931 shares of TG Therapeutics worth $655K as of Q2 2026.
  • MML Investors Services bought 5,527 TG Therapeutics shares in Q2 2026, an estimated $226K.
  • TG Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #2277 holding.
  • MML Investors Services first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.